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BIOPRINTING CARTILAGE GRAFTS 
Marcy Zenobi-Wong 
ETH Zürich, Zurich, Switzerland 
Bioprinting is an emerging technology for the fabrication of patient-specific, 
anatomically-complex tissues and organs. A novel bioink was developed based on 
two unmodified regulatory-compliant polysaccharides, gellan and alginate, which 
undergoes cell friendly gelation in the presence of cations. Rheological properties 
of the bioink revealed optimal shear thinning and shear recovery properties for 
high fidelity bioprinting. Tensile testing of bioprinted dumbbell-shaped specimens 
revealed a strong, ductile material. To make the bioink tissue-specific and bioacti-
ve, extracellular matrix particles can be added, or the polymers can be sulfated for 
growth factor binding affinity. As proof of concept, clinical product BioCartilage® 
(cartilage extracellular matrix particles) and bovine chondrocytes were added to the 
bioink. 3D auricular, nasal, meniscal and vertebral disc grafts were printed based 
on computer tomography (CT) data or generic 3D models. The bioink containing 
BioCartilage supported proliferation of chondrocytes and, in the presence of tran-
sforming growth factor beta-3 (TGF-β3), supported strong deposition of cartilage 
matrix proteins. A clinically-compliant bioprinting method is presented which yiel-
ds patient-specific cartilage grafts with good mechanical and biological properties. 
The versatile method can be used with any type of tissue particles to create tissue-
specific and bioactive scaffolds. 
3D CELL AND TISSUE CULTURING UNDER PERFUSION 
David Wendt
Cellec Biotek AG, Basel, Switzerland 
The in vitro culture of primary cells typically involves monolayer expansion 
on tissue culture plastic (e.g., on Petri dishes) and serial replating of the cells onto 
new dishes upon confluence. This technique fails to recapitulate a physiological en-
vironment and is associated with a loss of characteristics and functionality of the 
expanded cell progeny. Cell culture in a 3D setting (e.g., within the pores of 3D 
scaffolds), which in turn requires the use of perfusion-based bioreactor systems to 
maintain suitable mass transfer rates, has the potential to recapitulate features of a 
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physiological and pathological environment and thereby support cell functionality. 
This presentation will highlight the use of bioreactor-based 3D culture systems for 
applications including: (i) the expansion of progenitor cells while preserving their 
native properties (‘niche’ concept), (ii) the co-culture of different cell types, inclu-
ding those of the inflammatory/immune system, as well as (iii) the expansion of pri-
mary tumors and cell lines. These advanced 3D cell culture systems can represent 
organotypic tissue models based on human cells to investigate processes involved 
in tissue regeneration or disease modeling and treatment. The generated knowledge 
will be relevant to identify new strategies or compounds to instruct in situ regenera-
tion, as well as to restore pathologic conditions. 
BIOREACTOR-BASED CARTILAGE ENGINEERING 
David Wendt
Departments of Biomedicine and Surgery, University Hospital Basel, Basel, Switzerland 
Autologous Chondrocyte Implantation (ACI) and the second generation Ma-
trix-assisted ACI (MACI) have long been established in the clinic for the repair of 
cartilage injuries. However, as these products are manufactured with minimal in 
vitro pre-cultivation times, they contain little to no extracellular matrix and there-
fore lack the complex biological and mechanical signals which can be delivered by 
a more physiological mature tissue graft. Our laboratory has recently conducted 
a clinical trial based on mature cartilaginous engineered tissues for treatment of 
cartilage lesions, demonstrating the safety and feasibility of the tissue grafts. Howe-
ver, the manufacturing processes used to produce the engineered grafts were based 
on traditional bench-top manual culture methods, requiring a large number of la-
bor-intensive manipulations, which ultimately pose challenges towards regulatory 
compliance, process up-scaling, and long-term cost-effectiveness. As an alternative, 
bioreactor-based manufacturing systems, which automate and control the various 
bioprocesses, have the potential to overcome the limitations associated with con-
ventional manufacturing methods. Robust and streamlined bioreactor-based proce-
sses, as described in this presentation, will be key for the future manufacturing of 
cartilage grafts for clinical applications, as they facilitate the establishment of sim-
ple, compact, and closed manufacturing systems, with minimal user intervention 
required, lower operating costs, and increased compliance to safety guidelines. 
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